Avalon Global Asset Management LLC Takes Position in Edwards Lifesciences Corporation $EW

Avalon Global Asset Management LLC bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 55,000 shares of the medical research company’s stock, valued at approximately $4,302,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Bank of Nova Scotia boosted its holdings in shares of Edwards Lifesciences by 14.6% during the second quarter. Bank of Nova Scotia now owns 102,804 shares of the medical research company’s stock worth $8,040,000 after acquiring an additional 13,132 shares during the period. Baker Avenue Asset Management LP bought a new position in shares of Edwards Lifesciences during the second quarter worth approximately $212,000. California Public Employees Retirement System lifted its holdings in Edwards Lifesciences by 4.0% during the 2nd quarter. California Public Employees Retirement System now owns 962,759 shares of the medical research company’s stock worth $75,297,000 after purchasing an additional 37,259 shares during the last quarter. Cary Street Partners Investment Advisory LLC lifted its holdings in Edwards Lifesciences by 51.9% during the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 1,571 shares of the medical research company’s stock worth $123,000 after purchasing an additional 537 shares during the last quarter. Finally, Amundi boosted its stake in Edwards Lifesciences by 18.6% in the 2nd quarter. Amundi now owns 3,461,129 shares of the medical research company’s stock valued at $266,576,000 after purchasing an additional 541,943 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 0.6%

Shares of Edwards Lifesciences stock opened at $86.26 on Monday. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89. The company has a market capitalization of $50.05 billion, a price-to-earnings ratio of 37.18, a PEG ratio of 3.82 and a beta of 0.97. The firm’s 50-day moving average price is $80.95 and its two-hundred day moving average price is $78.76.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The company had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The firm’s quarterly revenue was up 14.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on EW shares. Royal Bank Of Canada increased their price objective on Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday. Wells Fargo & Company restated an “overweight” rating and issued a $96.00 price target (up from $95.00) on shares of Edwards Lifesciences in a research note on Friday. Truist Financial set a $92.00 price objective on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday. Oppenheimer downgraded shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 8th. Finally, Mizuho increased their target price on shares of Edwards Lifesciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average target price of $92.91.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $83.08, for a total value of $1,080,040.00. Following the sale, the chief financial officer owned 39,898 shares of the company’s stock, valued at approximately $3,314,725.84. This trade represents a 24.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 1,020 shares of Edwards Lifesciences stock in a transaction on Monday, November 10th. The shares were sold at an average price of $82.55, for a total value of $84,201.00. Following the completion of the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,816,265.10. The trade was a 4.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.34% of the stock is owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.